Clinical Trial Update: A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma [Phase 1]

View source ↗

Summary

A Phase 1 study of olaratumab (LY3012207) plus pembrolizumab in advanced or metastatic soft tissue sarcoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Olaratumab (olaratumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Soft Tissue Sarcoma | Phase 1 | Status: COMPLETED | Results posted: 2024-10-23